Drug condensation aerosols and kits
First Claim
1. A composition for delivery of a drug comprising a condensation aerosol a) formed by volatilizing a heat stable drug composition under conditions effective to produce a heated vapor of said drug composition and condensing the heated vapor of the drug composition to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 10% drug degradation products, and c) wherein the aerosol MMAD is less than 3 microns.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 μm, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.
195 Citations
82 Claims
-
1. A composition for delivery of a drug comprising a condensation aerosol
a) formed by volatilizing a heat stable drug composition under conditions effective to produce a heated vapor of said drug composition and condensing the heated vapor of the drug composition to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 10% drug degradation products, and c) wherein the aerosol MMAD is less than 3 microns.
- 20. A composition for inhalation therapy, comprising a condensation aerosol with a mixture of non-propellant, non-organic solvent carrier gas and condensation particles, formed from vaporization of a drug composition and characterized by less than 5% drug degradation products, and where the aerosol has an MMAD between 1-3 microns.
- 28. A composition for inhalation therapy, comprising an aerosol of vaporized drug condensed into particles, characterized by less than 5% drug degradation products, and wherein said aerosol has a mass median aerodynamic diameter between 1-3 microns.
-
48. A drug composition comprising an aerosol of a therapeutic drug, said aerosol containing
a) less than 5% drug degradation products, and b) a mixture of a carrier gas and condensation particles, formed by condensation of a vapor of the drug in said carrier gas; wherein the MMAD of the aerosol increases over time, within the size range of 0.01 to 3 microns as said vapor cools by contact with the carrier gas. - View Dependent Claims (49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)
-
68. A kit for delivering a drug condensation aerosol comprising:
-
a) a composition devoid of solvents and excipients comprising a heat stable drug compound in a unit dose form; and
b) a device for forming a drug aerosol, wherein the device for forming a aerosol comprises an element configured to heat the composition to form a vapor, an element allowing the vapor to condense to form a condensation aerosol, and an element permitting a user to inhale the condensation aerosol. - View Dependent Claims (69, 70, 71, 72, 73)
-
-
74. A kit for delivering a drug aerosol comprising:
-
a) a thin film of a drug composition and b) a device for dispensing said film as a condensation aerosol. - View Dependent Claims (75, 76, 77, 78, 79, 80, 81, 82)
-
Specification